So here is my prediction of cash position.
4.24m starting cash position
+ 1.3m tax rebate on R&D (although this could be less, they may not get all of it)
+ 90k receipts (double receipts from the SEP quarter) lower because I think the 130k in last quarter included some initial CBA revenue
+ 500k project receipts CBA (lower because there will be a cost of sale component to this revenue from a third party involved)
- 2m in payments (up from 1.69m in DEC quarter, due to cost of UK endeavours)
Cash on hand end of MAR quarter = 4.1m
This will become an issue will be the JUN quarter because CBA project revenue dries up, and the new subscriber volumes haven’t started generating any revenue yet, and the existing subscriber volume is only marginally increasing. So starting this quarter with 4.1m could see IN’s at only 140k, and the OUT’s payments at 2.4m leaving 1.8m in the kitty end of JUN quarter, not enough to last the next quarter.
- Forums
- ASX - By Stock
- $2,400,000 per year
So here is my prediction of cash position. 4.24m starting cash...
Featured News
Add DUB (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.1¢ |
Change
-0.002(8.70%) |
Mkt cap ! $43.99M |
Open | High | Low | Value | Volume |
2.3¢ | 2.3¢ | 2.0¢ | $149.4K | 6.970M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 2811746 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 942981 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 2811746 | 0.020 |
3 | 1152680 | 0.019 |
9 | 1886370 | 0.018 |
7 | 2128940 | 0.017 |
25 | 5928792 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 942981 | 1 |
0.022 | 152 | 1 |
0.023 | 101500 | 2 |
0.024 | 1693574 | 3 |
0.025 | 400000 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
DUB (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online